TY - JOUR
T1 - Immunotherapy for Melanoma
T2 - The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
AU - Fujimura, Taku
AU - Muto, Yusuke
AU - Asano, Yoshihide
N1 - Funding Information:
This study was supported in part by the Japan Agency for Medical Research and Development (22ym0126041h0002).
Publisher Copyright:
© 2022 by the authors.
PY - 2022/12
Y1 - 2022/12
N2 - Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as anchor drugs for treating advanced melanoma, with or without additional combination drugs such as ipilimumab, but the efficacies of these immunotherapies are not fully satisfactory. In this review, we describe the development of the currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (AEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma.
AB - Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as anchor drugs for treating advanced melanoma, with or without additional combination drugs such as ipilimumab, but the efficacies of these immunotherapies are not fully satisfactory. In this review, we describe the development of the currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (AEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma.
KW - advanced melanoma
KW - anti-CTLA4 Abs
KW - anti-PD1 Abs
KW - efficacy
KW - immune checkpoint inhibitors
KW - irAEs
UR - http://www.scopus.com/inward/record.url?scp=85144550547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144550547&partnerID=8YFLogxK
U2 - 10.3390/ijms232415720
DO - 10.3390/ijms232415720
M3 - Review article
C2 - 36555362
AN - SCOPUS:85144550547
SN - 1422-0067
VL - 23
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 24
M1 - 15720
ER -